Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | Insights into oral anticoagulant use and dementia risk

Presenting insights from a previous study, Alvi Rahman, PhD candidate, McGill University, Montreal, Canada, highlights a 10% decrease in dementia risk associated with oral anticoagulant (OAC) use in patients with nonvalvular atrial fibrillation. Follow-up research suggests that among OACs, direct oral anticoagulants (DOACs) are more effective than vitamin K inhibitors (VKAs) in reducing dementia risk, with no discernible differences observed among specific DOAC drugs in this regard. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.